Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

ne million men in the United States have prostate cancer, with an estimated 186,320 new cases expected to be diagnosed in 2008, and approximately 28,660 men expected to die this year from the disease. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... Winston-Salem, NC (PRWEB) March 30, 2015 ... Associates are pleased to announce the formation of ... clinical research centers specializing in the conduct of ... populations. VaxCorps clinical sites have successfully conducted ... extensive experience in seasonal and pandemic influenza as ...
(Date:3/30/2015)... 2015 US-Australian drug discovery company, Novogen Ltd, ... Inc., and Yale University, on March 27 released pre-clinical ... presented as an oral presentation by Professor Gil ... the 62 nd Annual Scientific Meeting of the ... CA. In both in vitro ...
(Date:3/30/2015)... (PRWEB) March 29, 2015 A two-day ... United States and plenary talks by four leading photonics ... Optics + Optoelectronics next month in Prague, Czech ... in 17 conferences alongside a two-day exhibition. Sponsored by ... , the event will run 13-16 April in the ...
(Date:3/29/2015)... , March 29, 2015  Caris Life ... in which Caris Molecular Intelligence®, the company,s panomic, ... and differences between several rare and difficult to ... that have the potential to improve patient outcomes. ... B at the Society of Gynecologic Oncology (SGO) ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4
... Biodel Inc. (Nasdaq: BIOD ) today reported ... Third Quarter Operating Highlights During ... completed Phase 1 testing of two new ultra-rapid-acting ... supported investigators at Oregon Health and Sciences University ...
... Inc. (NASDAQ: VRML ), a molecular diagnostics company, ... 30, 2011. Key milestones we have achieved since the last quarterly ... 3,920 OVA1® tests during the second quarter of 2011, exceeding ... of 27% over the first quarter of 2011. Publication ...
... novel carbon nanofiber-filled coatings devised by researchers from the ... A&M University outperformed conventional flame retardants used in the ... least 160 percent and perhaps by as much as ... the journal Polymer ,* suggest that significant fire-safety ...
Cached Biology Technology:Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 2Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 3Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 4Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 5Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 6Vermillion Reports Results for the Second Quarter 2011 2Vermillion Reports Results for the Second Quarter 2011 3Vermillion Reports Results for the Second Quarter 2011 4Vermillion Reports Results for the Second Quarter 2011 5Vermillion Reports Results for the Second Quarter 2011 6Vermillion Reports Results for the Second Quarter 2011 7Novel coatings show great promise as flame retardants in polyurethane foam 2
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
(Date:3/17/2015)... DIEGO , March 17, 2015 ... emotion analytics software, today announced general availability of ... web service for the analysis of facial expressions. ... experience advertising, media content, products and services. It ... attention, engagement and sentiment - as derived from ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... recently identified immune cell that directs other cells to ... immune system in both health and disease. Researchers from ... how a stimulatory molecule and a protein found on ... 17 cells multi-taskers of sorts. Th17 cells protect the ...
... Nanomedicine Center for Nucleoprotein Machines has received an award ... its renewal by the National Institutes of Health (NIH). ... of a clinically viable gene correction technology for single-gene ... disease. Sickle cell disease is a genetic condition ...
... To expand collaboration and initiatives, the 2010 Naval Science ... 8-10, will explore a wide range of cutting-edge solutions ... Hosted by the Office of Naval Research, the three-day ... Crystal City, Va., and will feature a lineup of ...
Cached Biology News:Penn study shows 2-sided immune cell could be harnessed to shrink tumors 2NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 2NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 3NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 4
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
...
Biology Products: